Drug intelligence / Profile preview

H8

Development stage: Preclinical
Modality: Small Molecules

Overview

H8 is a curcumin analog that functions as a selective inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1). It has demonstrated therapeutic potential in mitigating lipid metabolism disorders by reducing glucocorticoid levels and activating the AMP-activated protein kinase (AMPK) signaling pathway. Its effects include diminishing lipid accumulation and altering markers of lipid synthesis, as observed in both in vitro and in vivo models.

Other names: curcumin analog

Targets

AMPK (Adenosine monophosphate–activated protein kinase)HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)

Beyond the preview

Go deeper on H8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H8.

Explore the full profile